| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Sales | 748 | 1,004 | 1,018 | 6,854 |
| Cost of goods sold | 732 | 1,005 | 734 | 467,536 |
| Gross profit (loss) | 16 | -1 | 284 | -460,682 |
| General and administrative expenses 0, 32, 0, and 28,670 in stock-based compensation, respectively | 2,462,561 | 5,039,036 | 4,348,274 | 3,718,804 |
| Research and development 0, 0, 10,000 and 6,712,663 in stock-based compensation, respectively | 672,045 | 764,327 | 1,209,205 | 491,552 |
| Sales and marketing 0, 0, 473,311, and 0 in stock-based compensation, respectively | 6,040 | 349,031 | 50,920 | 30,000 |
| Total operating expenses | 3,140,646 | 6,152,394 | 5,608,399 | 4,240,356 |
| Net loss from operations | -3,140,630 | -6,152,395 | -5,608,115 | -4,701,038 |
| Interest expense | 176,527 | 47,352 | 157,499 | 570,114 |
| Interest income | 183,631 | 78,566 | 288 | 376 |
| Amortization of debt discount | 234,167 | 1,212,246 | 200,284 | 1,709,537 |
| Gain (loss) on note exchange agreement | - | 0 | - | - |
| Change in fair value of derivative liability | -162 | -980 | -13,145 | - |
| Change in fair value of evofem warrants | -2,511,781 | 63,211 | - | - |
| Impairment of evofem f-1 preferred stock | 23,001,919 | - | - | - |
| Credit loss on evofem notes | 350,000 | - | - | - |
| Total other expense | -21,067,039 | -1,243,263 | -344,350 | -2,279,275 |
| Net loss before income taxes | -24,207,669 | -7,395,658 | -5,952,465 | -6,980,313 |
| Income tax provision | - | 0 | - | - |
| Net loss | -24,207,669 | -7,395,658 | -5,952,465 | -6,980,313 |
| Net loss attributable to non-controlling interest | -162,264 | -138,850 | -242,156 | -39,801 |
| Implied dividends | - | - | - | -5,907,011 |
| Net loss attributable to aditxt, inc. & subsidiaries | -24,045,405 | -7,256,808 | -5,710,309 | -12,847,523 |
| Net loss per share - diluted (in dollars per share) | -548.78 | -3.45 | -8.12 | -111.07 |
| Net loss per share, basic (in dollars per share) | -548.78 | -3.45 | -8.12 | -111.07 |
| Weighted average number of shares outstanding during the period - diluted (in shares) | 43,816 | 2,101,701 | 703,666 | 115,672 |
| Weighted average number of shares outstanding during the period, basic (in shares) | 43,816 | 2,101,701 | 703,666 | 115,672 |
Aditxt, Inc. (ADTX)
Aditxt, Inc. (ADTX)